Research Program: Cancer Immunology

研究项目：癌症免疫学

基本信息

批准号：
10636821
负责人：
Marie Bleakley
金额：
$ 8.3万
依托单位：
FRED HUTCHINSON CANCER CENTER
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
起止时间：
1997-01-01 至 2024-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10636821
关键词：
Adoptive Immunotherapy Adult Antibodies Antigen Targeting Appointment Blood Cancer Center Support Grant Cell Therapy Cell physiology Cell surface Cells Cellular immunotherapy Center Core Grants Child Clinical Clinical Trials Complex Coupled Development Direct Costs Down-Regulation Engineering Evaluation Faculty Funding Genetic Engineering Grant Hematologic Neoplasms Hematopoietic Stem Cell Transplantation Immune Immune Evasion Immune system Immunity Immunologics Immunology Immunotherapeutic agent Immunotherapy Institution Investigation Investments Malignant Childhood Neoplasm Malignant Neoplasms Mediating Metabolic Modality Modeling Myelogenous Nanotechnology Nature Neoplasm Metastasis Paper Patients Pediatric Hematology Peer Review Peptide/MHC Complex Pre-Clinical Model Property Publishing Regulatory T-Lymphocyte Research Research Infrastructure Research Personnel Research Project Grants Research Support Resistance Resource Sharing Resources Role Safety Sampling Science Signal Transduction Solid Neoplasm Specimen T cell therapy T-Cell Receptor T-Lymphocyte Therapeutic Translating Transplantation Tumor Tissue Turtles Universities Washington Work cancer cell cancer immunotherapy chimeric antigen receptor clinical application clinical infrastructure design effector T cell engineered T cells first-in-human genetic manipulation humanized mouse immune checkpoint blockade improved insight meetings member neoplastic cell next generation novel pre-clinical programs receptor recruit response small molecule success synthetic biology therapeutically effective tumor tumor eradication tumor immunology tumor progression vaccine strategy

项目摘要

PROJECT SUMMARY: CANCER IMMUNOLOGY (CI) Over the past decade, immunotherapy has emerged as an established modality that is revolutionizing the treatment of many cancers. The Cancer Immunology (CI) Research Program has focused on genetically manipulating T cells, applying new principles of synthetic biology, and combining engineered T cells with small molecules and antibodies to broaden the applications and improve the safety and efficacy of adoptive immunotherapy. Despite the success achieved with immunologic approaches in treating some malignancies, major gaps exist in our current understanding of the complex relationship between progressing tumors and host immunity, and these must be understood and overcome to achieve the potential of immunotherapy in many common cancers. The CI program will focus on systematically tackling these barriers to eradicating tumors using a variety of immunotherapeutic modalitie alone and in combination. The specific aims of CI are (1) to develop effective and safe cellular immunotherapies for adult and pediatric hematologic malignancies and solid tumors, (2) to identify and overcome the barriers to immune-mediated tumor eradication using clinical specimens and preclinical models, (3) to translate discoveries in basic immunology and synthetic biology to novel clinical applications in cancer immunotherapy. The Cancer Immunology (CI) program currently has 39 members from 11 departments and divisions and 4 Consortium institutions. Nineteen members have primary appointments at Fred Hutch, 12 members at University of Washington, and 8 members at Seattle Children’s. Fourteen new faculty members joined this program in the last cycle. The current research support of CI members is $23.4M (direct costs) in research grant funding, of which $4.4M (19%) is from the NCI and $7.8M (33%) is peer reviewed. The Cancer Immunology program published a total of 470 papers in the last grant period, of which 14% were intra- programmatic, 49% were inter-programmatic, and 50% had external co-authors. Program members have utilized all 12 of the Consortium Shared Resources. This P30 grant also assists this program by providing administrative and logistical support for CI meetings, pilot funding for new research projects, and recruitment resources for new faculty.

项目摘要：癌症免疫学（CI）在过去的十年中，免疫疗法已成为一种已建立的方式，正在彻底改变许多癌症的治疗。癌症免疫学（CI）研究计划的重点是基因操纵T细胞，应用合成生物学的新原理，并将工程的T细胞与小分子和抗体扩大应用并提高自适应的安全性和效率免疫疗法。尽管通过免疫方法在治疗某些恶性肿瘤方面取得了成功，但我们目前对进展肿瘤和宿主免疫学，必须理解并克服这些免疫学，以实现免疫疗法的潜力许多常见的癌症。 CI计划将集中于系统地应对这些障碍以消除单独和组合使用各种免疫治疗模态。 CI的具体目的是（1）为成人和小儿血液学恶性肿瘤开发有效且安全的细胞免疫疗法（2）使用临床识别和克服免疫介导的消除肿瘤的障碍标本和临床前模型，（3）将基本免疫学和合成生物学的发现转化为癌症免疫疗法中的新型临床应用。癌症免疫学（CI）计划目前有来自11个部门和部门的39名成员，4个成员财团机构。十九名成员在弗雷德·哈奇（Fred Hutch）有主要任命，有12名成员在华盛顿大学和西雅图儿童的8位成员。十四位新教师加入了这个在最后一个周期中的程序。 CI成员的当前研究支持为2340万美元（直接费用）赠款资金，其中440万美元（19％）来自NCI，并审查了780万美元（33％）。癌症免疫学计划在上一个赠款期间发表了470篇论文，其中14％是内部的程序化，49％是程序间截面，有50％的外部合着者。计划成员有利用了所有共享资源的全部12个。该P30赠款还通过提供 CI会议的行政和后勤支持，新研究项目的试点资金以及招聘新教师的资源。